September 1, 2023

XLock Biosciences’ CEO Dr. William Clarke has been awarded a Direct to Phase II SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases in the of $1.99M for his project titled “Targeting the CCR6-CCL20 pathway for treatment of psoriatic joint and entheseal inflammation”.